Orforglipron vs Semaglutide

Mechanism: peptide vs small-molecule at the same receptor

Both drugs activate the GLP-1 receptor: the gut-hormone pathway that slows gastric emptying, suppresses appetite via hypothalamic signaling, and amplifies meal-triggered insulin secretion. The difference is the molecule. Semaglutide is a 31-amino-acid peptide modified with a fatty acid chain so it binds albumin and stays in circulation ~165 hours (once-weekly dosing). Orforglipron is a small-molecule (non-peptide) agonist: a single chemical structure that binds the same receptor but isn't a protein, so it survives stomach acid intact and absorbs orally without the strict fasting protocol Rybelsus requires. Same receptor, same downstream effects; different pharmacology around how the drug gets there.

• Semaglutide: Peptide GLP-1RA, subQ once weekly or a daily tablet, ~165h half-life, albumin-bound for long duration
• Orforglipron: Non-peptide GLP-1RA, oral daily, no fasting/water requirement (the semaglutide tablets need a 30-min wait)
• Both: Same receptor target → same core mechanism of weight loss + glycemic control

Efficacy: trial readouts and the one head-to-head

Semaglutide's STEP-1 trial (NEJM 2021, 1,961 adults with obesity) showed 14.9% mean body-weight loss at 2.4 mg weekly over 68 weeks. Orforglipron's ATTAIN-1 trial (NEJM September 2025, 3,127 adults with obesity and no diabetes) showed 11.2% at the 36 mg daily dose over 72 weeks for everyone randomized, against 2.1% on placebo, and 12.4% for people who stayed on treatment. The 14.7% figure that still gets quoted for orforglipron is the top result from its smaller 36-week Phase 2 trial (NEJM 2023, 272 adults). Novo's own pill, oral semaglutide 25 mg, was tested in OASIS 4 (NEJM 2025, 307 adults, also with no diabetes) over 64 weeks rather than 72: 13.6% for everyone randomized and 16.6% for people who stayed on treatment, against orforglipron's 11.2% and 12.4%. The only head-to-head so far, ACHIEVE-3 (Lancet 2026, 1,698 adults with type 2 diabetes on metformin), ran orforglipron 12 and 36 mg against oral semaglutide 7 and 14 mg for 52 weeks, and both orforglipron doses lowered HbA1c more than both semaglutide doses. In a separate T2D-only trial (ACHIEVE-1, NEJM 2025), orforglipron 36 mg lowered HbA1c by 1.5%. Against Wegovy 2.4 mg the weight-loss gap is real but small, a few points in semaglutide's favor, and the 7.2 mg Wegovy HD dose approved in March 2026 goes further (18.8% at 72 weeks on its label). Tirzepatide and retatrutide still beat both on absolute weight loss; among GLP-1 mono-agonists the top number now belongs to semaglutide at 7.2 mg.

• Semaglutide @ 2.4 mg (68 wk): 14.9% mean body-weight loss (STEP-1)
• Orforglipron @ 36 mg (72 wk): 11.2% mean body-weight loss, 12.4% if you stay on treatment (ATTAIN-1)
• HbA1c (T2D adults): ACHIEVE-3 head-to-head: orforglipron 36 mg cut it 1.91 points vs 1.47 for oral semaglutide 14 mg (52 wk)

Dosing: daily pill vs weekly injection

Semaglutide titrates 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg subQ weekly, escalating every 4 weeks, and since March 2026 adults who have tolerated 2.4 mg for at least 4 weeks can step up to 7.2 mg (Wegovy HD) if they need more weight loss. Wegovy's single-dose pens and syringes are kept in the fridge and can sit at room temperature for up to 28 days, while the four-dose Wegovy FlexTouch pen and an Ozempic pen last 56 days once you start them. Foundayo, the approved orforglipron tablet, starts at 0.8 mg daily, moves to 2.5 mg and then 5.5 mg after at least 30 days on each, and can go up to 9, 14.5 or a maximum 17.2 mg based on response and tolerability. The label strengths are not the trial numbers: Foundayo's label describes the ATTAIN-1 arms, published as 6, 12 and 36 mg, as its 5.5, 9 and 17.2 mg doses. No food restriction, no water timing, no needle. The clinically meaningful tradeoff: orforglipron's daily dosing means missing a dose is a one-day blip; missing semaglutide means a half-week of suboptimal coverage.

• Semaglutide titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg subQ weekly, +1 step every 4 weeks; 7.2 mg (Wegovy HD) after 4+ weeks on 2.4 mg
• Orforglipron titration: Foundayo label: 0.8 → 2.5 → 5.5 mg daily, then 9, 14.5 or 17.2 mg; 30 days minimum per step
• Convenience: Orforglipron: room-temp stable, no needle, no fasting window (unlike the semaglutide tablets)

Safety: same GI profile, slightly different tails

Both drugs share the standard GLP-1 side-effect profile: nausea, vomiting, diarrhea, and constipation. Severity peaks during titration and fades by week 4 of each new dose. Across the 5.5, 9 and 17.2 mg doses on Foundayo's label, nausea ran 26-35%, constipation 20-27%, diarrhea 21-25% and vomiting 13-24%, against 10%, 9%, 11% and 4% on placebo. Wegovy's label puts nausea at 44%, diarrhea at 30%, vomiting at 24% and constipation at 24% for the 2.4 mg injection. Those are separate trials, and at Foundayo's top 17.2 mg dose vomiting (24%) and constipation (24%) match Wegovy, while nausea (35%) and diarrhea (25%) run lower. The one head-to-head trial, ACHIEVE-3 in type 2 diabetes, found more gastrointestinal side effects on orforglipron 36 mg than on oral semaglutide 14 mg (58% vs 45%). Side effects made 8% of patients stop Foundayo across its doses (10% at 17.2 mg, 3% on placebo) and 6.8% stop Wegovy 2.4 mg injection (3.2% on placebo); in ACHIEVE-3 it was 10% against 5%. Both carry the boxed thyroid C-cell tumor warning, with no confirmed human signal: semaglutide caused these tumors in rodents, while orforglipron is not active at the rat or mouse receptor and caused none, so its warning comes from the drug class. ACHIEVE-4 (April 2026) ran orforglipron against insulin glargine for up to 104 weeks in 2,749 adults with type 2 diabetes, overweight or obesity and increased cardiovascular risk. It met its cardiovascular non-inferiority endpoint (hazard ratio 0.84, 95% CI 0.59 to 1.20) and found no liver safety signal. The roughly 4% who drop semaglutide for GI tolerance will likely have the same problem with orforglipron; it's the GLP-1 receptor agonism causing GI effects, not the molecular structure.

• Shared GI profile: Nausea, vomiting, diarrhea, constipation; worst during titration
• Label rates: Foundayo nausea 26-35%, constipation 20-27%; Wegovy nausea 44%, constipation 24%
• Shared boxed warning: Thyroid C-cell tumor risk; contraindicated with a personal or family history of MTC, or with MEN 2
• Cardiovascular: ACHIEVE-4 met CV non-inferiority vs insulin glargine (HR 0.84) over up to 104 weeks

Cost: what you actually pay in 2026

Semaglutide list prices in 2026: Wegovy ~$1,350/month, Ozempic ~$1,000/month at a US pharmacy. Self-pay runs far below list: Novo cut both to $349/month in November 2025 (Ozempic 2 mg stayed $499), and the Wegovy pill's 1.5 mg starting dose launched at $149/month with savings offers. Insurance coverage is broad for T2D but mixed for obesity. Compounded semaglutide wound down in 2025, after the FDA declared the shortage resolved on February 21, 2025 and gave compounding pharmacies until April 22 and outsourcing facilities until May 22 to stop; some research-use channels still operate at $0.50-1.50/mg. Orforglipron has been FDA-approved as Foundayo since April 1, 2026, and Lilly's launch pricing is as little as $25/month with commercial insurance and its savings card, self-pay starting at $149/month for the lowest dose, and $50/month for eligible Medicare Part D patients through the Medicare GLP-1 Bridge program, which began July 1, 2026 and runs through December 31, 2027. Right now both are prescription options; research-grade orforglipron still moves through gray-market channels at ~$15-30/month worth of compound.

• Semaglutide list price: Wegovy ~$1,350/mo, Ozempic ~$1,000/mo; Wegovy self-pay $149-399/mo by form and dose; insurance varies by indication
• Orforglipron retail: Foundayo: self-pay from $149/mo for the lowest dose, as little as $25/mo with commercial insurance
• Research-use today: Both available in research-grade; orforglipron ~$0.50/mg, semaglutide $0.50-1.50/mg

Who chooses which today

If you need a pharmacy-filled GLP-1 in 2026, both work: semaglutide as Wegovy, either the weekly shot or the daily pill, and orforglipron as Foundayo. Whether you are choosing a prescription or a research-use molecule, the case for orforglipron is convenience (oral, no needles, no fasting, room-temp stable for travel) at a few points less average weight loss. The case for semaglutide is the bigger average weight loss in obesity trials (more again at 7.2 mg), the longer US record (semaglutide since 2017 as Ozempic, Wegovy since June 2021) and the wider published evidence base across populations. With both sold as pills, the needle is no longer the deciding factor: frequent travelers and anyone who dislikes the empty-stomach rule default to orforglipron; users who want maximum-validated long-term data stay on semaglutide.